Venom and Antivenom of the Redback Spider (Latrodectus hasseltii) in Japan. Part II. Experimental Production of Equine Antivenom against the Redback Spider.

The research article discusses how scientists in Japan successfully produced a large-scale experimental antivenom against the venom of redback spiders. They used 10,000 redback spiders for venom extraction, and the antivenom was developed by injecting horses with the venom to trigger an immune response and harvesting the resultant antitoxin.

Methodology

• The researchers began by obtaining 10,000 redback spiders from various locations in Japan. They subsequently extracted crude venom from these arachnids to be used in the creation of what are known as toxoids.
• To make the venom less harmful but still capable of triggering an immune response, they transformed it into toxoids through a specific treatment procedure. These toxoids were then mixed with mineral oil adjuvants, substances that stabilize and increase the effectiveness of vaccines.
• Several healthy horses were then repeatedly immunized with this mixture over an extended period. The aim was to trigger an immune response in the horses, leading to the production of specific antibodies against the venom toxoids.
• The researchers then harvested the horse plasma, which carried these antibodies. They followed with a purification process to isolate the γ-globulin fraction, which is the portion of the blood’s protein fraction that contains the majority of the antibodies.

Creation of Antivenom

• The scientists stored the purified γ-globulin fraction containing the antitoxin, intending to use it for the mass production of the antivenom.
• This process led to the production of approximately 6,500 vials of a single-dose freeze-dried test lot from a portion of the purified γ-globulin fraction. This amount equates to the extract derived from 520 spiders.

Quality Analysis

• The antivenom produced underwent thorough testing to ensure quality. The researchers have stated that the antitoxin titer, or the concentration of antitoxin in the antivenom, was comparable to that of a similar liquid preparation product available commercially overseas.
• Furthermore, the produced antivenom met all quality reference specifications. These were based on the Minimum Requirements for Biological Products and other guidelines that are relevant to the existing antivenom drug products in Japan.

In summary, the article discusses the successful large-scale experimental production of antivenom against redback spider venom using a method that involves immunizing horses with venom toxoids and subsequently harvesting and purifying the produced antitoxin from their plasma.